Andes 1537

Drug Profile

Andes 1537

Alternative Names: Andes-1537

Latest Information Update: 28 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Andes Biotechnologies
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 24 Dec 2015 Andes 1537 is available for licensing as of 24 Dec 2015. http://www.andesbio.com/
  • 01 Dec 2015 Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (SC)
  • 16 Apr 2015 Preclinical trials in Solid tumours in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top